Rephonic
Artwork for Lung Cancer Update

Lung Cancer Update

Dr. Neil Love
Non-Small Cell Lung Cancer
Immunotherapy
Lung Cancer
Small Cell Lung Cancer
Chemotherapy
Pembrolizumab
Egfr
Targeted Therapy
Osimertinib
EGFR Mutations
Antibody-Drug Conjugates
Antibody Drug Conjugates
Adjuvant Therapy
Clinical Trials
Neoadjuvant Chemotherapy
EGFR Mutation
Alk-Targeted Therapy
Adora Trial
Nivolumab
Pd-L1 Expression

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.

PublishesTwice weeklyEpisodes359Founded20 years ago
Number of ListenersCategories
ScienceHealth & FitnessMedicine

Listen to this Podcast

Artwork for Lung Cancer Update

Latest Episodes

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics:

• Introduction (0:00)

• Optimizing First-Line and Maintenance Therapy for Extensiv... more

YouTube

Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:

• Introduction: Relative Impact of Targeted Treatment (00:00)

• HER2 Alterations (8:04)

• KRAS Mutations (24:25)

• MET Overexpression (30:34)

• ALK F... more

Featuring perspectives from Dr Joshua K Sabari, including the following topics:

• Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patie... more

Featuring perspectives from Dr Joshua K Sabari, including the following topics:

• Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med 2025;392(23):2321-33. (0:00)

• Popat S et al. Zongertinib as f... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Recent Guests

Charu Agarwal
Oncologist from University of Pennsylvania
University of Pennsylvania
Episode: Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Tisiana Leal
Oncologist from Emory University
Emory University
Episode: Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Dr. Joshua Sabari
Oncologist at NYU Langone Health Permutter Cancer Center
NYU Langone Health Permutter Cancer Center
Episode: HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 3
Dr. Antonio Passaro
Lecturer presenting first-line blocks and data on EGFR-mutant NSCLC
Division of Thoracic Oncology, European Institute of Oncology
Episode: EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Dr. Susmita Appori
Presenter of community cases focusing on upfront treatment decisions
General medical oncology
Episode: EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Dr. Fred Divers
Case presenter regarding EGFR-mutant NSCLC with chemotherapy and TKIs
Medical oncology practice
Episode: EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Dr. Priya Rudolph
Case presenter focusing on brain metastases and CNS management
Academic medical center
Episode: EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Joshua Sabari
Physician from NYU Langone Health Perlmutter Cancer Center
NYU Langone Health Perlmutter Cancer Center
Episode: HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review
Mark Jeng
Physician from Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Episode: HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review

Host

Dr. Neil Love
Host of the podcast series; conducts one-on-one interviews and moderates discussions across thoracic oncology topics

Reviews

4.6 out of 5 stars from 47 ratings
  • Medicine resident subscriber

    Third year medicine resident applying to Heme onc fellowship. I am interested in lung cancer and this podcast inspires critical thinking about patient management and provokes thought about the lung cancer literature. Uniquely has fantastic interviews with experts in the field. A great listen. I recommend this to anyone interested in oncology and interested in improving their knowledge of lung cancer management.

    Apple Podcasts
    5
    MG2MD
    United States8 years ago
  • Heldere informatie over longkanker

    Hier ben ik heel blij mee.

    Ik wou dat zoiets in het Nederlands bestond.

    Apple Podcasts
    5
    Thea 1953
    Netherlands14 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Fans appreciate the breadth of topics from targeted therapies to CNS considerations and liquid biopsy.
Listeners praise in-depth expert interviews and practical guidance for real-world lung cancer management.
Audiences value case-based discussions and data interpretation that help translate trials into patient care.

Top Science Podcasts

Radiolab
RadiolabWNYC Studios
Something You Should Know
Something You Should KnowMike Carruthers | OmniCast Media
Hidden Brain
Hidden BrainHidden Brain, Shankar Vedantam
StarTalk Radio
StarTalk RadioNeil deGrasse Tyson
Science of Perception Box
Science of Perception BoxUnlikely Collaborators | Pod People
Science Friday
Science FridayScience Friday and WNYC Studios
Big Ideas Lab
Big Ideas LabMission.org
Science Vs
Science VsSpotify Studios

Talking Points

Recent interactions between the hosts and their guests.

HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review
Q: What do we know about sequencing HER2-targeted therapies if a patient progresses on one agent—can they still respond to another later on?
There is limited head-to-head data, but real-world and cross-trial observations suggest activity can persist with different mechanisms of action; for example, responses to Trastuzumab Deroxetecan after TKIs and vice versa may occur, underscoring the importance of sequencing based on mechanism and prior responses.
HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review
Q: So when deciding which HER2-directed agent to use in the first-line setting, how do you choose between Zongurtinib and Seviburtinib and what are the CNS considerations?
In first-line care, Zongurtinib is favored due to its favorable tolerability profile and compelling CNS activity data, with Seviburtinib offering similar targeted action but higher GI toxicity and less robust CNS evidence; decisions should factor in CNS involvement, patient tolerance, and potential CNS protection.
HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 3
Q: Jason, can you talk a little about what they looked at and saw in the ctDNA dynamics study?
Circulating tumor DNA advances showed a clear drop in the mutant clone after Zongurtinib started, indicating rapid systemic activity, while progression could be tracked in real time by rising allele frequencies, though the clinical implications of stopping therapy remain uncertain.
Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft
Q: How should clinicians interpret the role of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy?
Adjuvant immunotherapy may be beneficial in selected patients, particularly those without a pathologic complete response, but robust prospective data to isolate the adjuvant contribution are lacking; decisions should consider PD-L1 status, tumor biology, and patient risk/benefit profile.
Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft
Q: What are the most important data points from perioperative immunotherapy trials that clinicians should apply in practice?
Key takeaways include the consistent improvements in pathologic response rates and some signals for improved survival in several perioperative studies, though attributing benefit specifically to induction vs adjuvant phases remains challenging; PD-L1 status remains a useful but not absolute predictor, and decisions should be individualized based on patient fitness, mutation status, and surgical goals.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Lung Cancer Update

What is Lung Cancer Update about and what kind of topics does it cover?

Clinician-to-clinician conversations feature leading medical oncologists and thoracic oncology experts discussing the latest data, trial results, and real-world management of lung cancer across subtypes. Episodes cover targeted therapies (EGFR, HER2, ROS1, RET), small cell lung cancer, CNS involvement, liquid biopsy and ctDNA, immunotherapy strategies, and antibody-drug conjugates, with practical case discussions and sequencing decisions. The show often emphasizes balancing efficacy with tolerability, translating research into patient care, and exploring emerging therapies and trial results from major conferences. A notable strength is the breadth of senior clinician perspectives, practical insights from community practice, and a clear focu... more

Where can I find podcast stats for Lung Cancer Update?

Rephonic provides a wide range of podcast stats for Lung Cancer Update. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Lung Cancer Update and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Lung Cancer Update get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for Lung Cancer Update, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Lung Cancer Update?

Rephonic provides comprehensive predictive audience data for Lung Cancer Update, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Lung Cancer Update have?

To see how many followers or subscribers Lung Cancer Update has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Lung Cancer Update?

These podcasts share a similar audience with Lung Cancer Update:

1. Gastrointestinal Cancer Update
2. Lung Cancer Considered
3. Two Onc Docs
4. Prostate Cancer Update
5. Oncology Today with Dr Neil Love

How many episodes of Lung Cancer Update are there?

Lung Cancer Update launched 20 years ago and published 359 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Lung Cancer Update?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Lung Cancer Update?

Rephonic pulls ratings and reviews for Lung Cancer Update from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Lung Cancer Update?

Rephonic provides full transcripts for episodes of Lung Cancer Update. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Lung Cancer Update?

Recent guests on Lung Cancer Update include:

1. Charu Agarwal
2. Tisiana Leal
3. Dr. Joshua Sabari
4. Dr. Antonio Passaro
5. Dr. Susmita Appori
6. Dr. Fred Divers
7. Dr. Priya Rudolph
8. Joshua Sabari

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days